Free Trial

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent logo
$95.62 +0.69 (+0.73%)
(As of 11/25/2024 ET)

Nuvalent - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
1
Buy
11

Based on 13 Wall Street analysts who have issued ratings for Nuvalent in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 1 has given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for NUVL.

Consensus Price Target

$112.60
17.76% Upside
According to the 13 analysts' twelve-month price targets for Nuvalent, the average price target is $112.60. The highest price target for NUVL is $135.00, while the lowest price target for NUVL is $97.00. The average price target represents a forecasted upside of 17.76% from the current price of $95.62.
Get the Latest News and Ratings for NUVL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nuvalent and its competitors.

Sign Up

NUVL Analyst Ratings Over Time

TypeCurrent Forecast
11/26/23 to 11/25/24
1 Month Ago
10/27/23 to 10/26/24
3 Months Ago
8/28/23 to 8/27/24
1 Year Ago
11/26/22 to 11/26/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
10 Buy rating(s)
9 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$112.60$112.40$91.88$60.86
Forecasted Upside17.76% Upside23.93% Upside9.01% Upside-3.84% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy

NUVL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NUVL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Nuvalent Stock vs. The Competition

TypeNuvalentMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside17.76% Upside17,640.32% Upside6.38% Upside
News Sentiment Rating
Neutral News

See Recent NUVL News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2024BMO Capital Markets
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$132.00 ➝ $134.00+47.27%
11/12/2024Wedbush
4 of 5 stars
 Reiterated RatingOutperform$115.00+26.39%
10/24/2024UBS Group
4 of 5 stars
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$100.00+6.71%
10/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$100.00 ➝ $125.00+19.96%
9/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Law
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
9/16/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$99.00 ➝ $105.00-2.07%
9/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$115.00 ➝ $135.00+54.37%
8/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Lawson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$100.00+18.11%
7/29/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$97.00+50.48%
4/1/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
4/1/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$69.00 ➝ $110.00+46.49%
2/23/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$105.00+26.16%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$42.00-5.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:41 PM ET.


NUVL Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Nuvalent is $112.60, with a high forecast of $135.00 and a low forecast of $97.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There is currently 1 sell rating, 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NUVL shares.

According to analysts, Nuvalent's stock has a predicted upside of 17.76% based on their 12-month stock forecasts.

Over the previous 90 days, Nuvalent's stock had 1 upgrade by analysts.

Nuvalent has been rated by research analysts at Barclays, BMO Capital Markets, Guggenheim, JPMorgan Chase & Co., Stifel Nicolaus, The Goldman Sachs Group, UBS Group, and Wedbush in the past 90 days.

Analysts like Nuvalent more than other "medical" companies. The consensus rating score for Nuvalent is 2.85 while the average consensus rating score for "medical" companies is 2.80. Learn more on how NUVL compares to other companies.


This page (NASDAQ:NUVL) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners